RE:RE:RE:AstraZeneca's ADC disappoints - on severe adverse eventsIn addressing Pfizer's loss of marketing exclusivity due to patent expiration of its main revenue drivers and the loss of small molecule predominance with the passing of the IRA in 2022, Pfizer's new plan is to focus on four main cancer types—breast cancer, genitourinary cancer, blood cancer and thoracic cancers—all of which the company already has commercial products in.
Before the Seagen deal, Pfizer’s top three cancer drugs—Ibrance, Xtandi and Inlyta—were all small molecules. Now, the New York pharma aims to increase the proportion of biologics in its revenue mix from 6% to 65% by 2030.
Despite growth potential from the new drugs, the Ibrance patent cliff will be so steep that Pfizer expects breast cancer’s contribution to total oncology sales will drop to about 10% by 2030 from about 40% in 2023.
In 2023, Pfizer’s oncology sales dropped 3% at constant exchange rates to $11.6 billion, despite a small contribution from the Seagen products in the last few days of 2023. Declines from Ibrance and Xtandi collaboration revenue drove the overall decrease.
https://www.fiercepharma.com/pharma/pfizer-fleshes-out-oncology-strategy-targeting-8-blockbuster-cancer-drugs-2030